[Abstract Only] Randomized Trial: GLP-1 Receptor Agonist and Cardiovascular Outcomes in Type 2 Diabetes

11 Jun, 2019 | 03:01h | UTC

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial – The Lancet (link to abstract – $ for full-text)

Commentary: Dulaglutide Cuts Cardiovascular Risk in Type 2 Diabetes – NEJM Journal Watch (free)

During a median follow-up of 5.4 years, the primary outcome (a composite endpoint of non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular causes) occurred in 12.0% of participants in the dulaglutide group and in 13.4% of participants in the placebo group (incidence rate of 2.4 per 100 person-years vs 2.7 per 100 person-years in the placebo group).

 

Join our WhatsApp group

Updates in All Specialties

Stay Updated in Your Specialty
No spam, just news
Unsubscribe with one click

 

Daily

 

Weekly or Less Often 
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •